36 results about "Oncotic pressure" patented technology

A peritoneal-based (“bloodless”) artificial kidney processes peritoneal fluid without need for additional fluids (“waterless”). Fluid is separated into a protein-rich stream and a protein-free stream. The protein-rich stream is regenerated using a sorbent assembly, and its protein composition can be modified by removal of selected protein(s) (“dialysate-pheresis”). It is then reconstituted with additives and returned into the peritoneal cavity, thereby reducing protein-loss and providing oncotic-pressure for ultrafiltration. The protein-free stream is used to produce free water, and an alkaline or acid fluid for optimization of the composition of the regenerated stream. The unused protein-free stream can be used to “reverse flush” the separator to maintain its patency and the excess discarded for fluid-balance regulation. Compared to prior art, immobilization of urease allows more protein rich fluid to be regenerated and re-circulated into the peritoneal cavity for toxin removal and allows practicable development of portable and wearable artificial kidneys.

The invention discloses novel application for Ectoine, namely application of the Ectoine in preparing medicines of treating hepatitis or hepatocirrhosis. The effective dosage range of the Ectoine is 0.1 to 100 mg / kg of body weight, preferably 8 to 50mg / kg of the body weight. When in use, the Ectoine adopts a mode of intravenous infusion. The experiment implemented by the inventor proves that the Ectoine can protect hepatic tissue, and inhibit the reduction of albumin, other proteins, amino acid, thrombozyme and profibrinolysin in liver and serum when the hepatitis and the hepatocirrhosis develop, thereby maintaining normal colloid osmotic pressure, delaying the generation of ascites, improving the content of RNA in the liver and achieving the aims of protecting the liver and controlling the growth of the disease of the hepatitis and the hepatocirrhosis. The Ectoine can be used for assisting treatment of the hepatitis and the hepatocirrhosis.

The invention relates to a biological macromolecule optical detection method related to intracellular colloid osmotic pressure, and construction and applications of a drug screening method related tothe biological macromolecule optical detection method. According to the present invention, the size, the shape, the position and the number of myosin, tubulin and other biological macromolecule particles or particle aggregates rich in cells or the density and the strength of protein markers are subjected to optical detection or imaging detection so as to evaluate the change of the intracellular colloid osmotic pressure and the regional mapping; with the optical detection method for the biological macromolecules related to intracellular colloid osmotic pressure, the change of the intracellularcolloid osmotic pressure can be analyzed, and the compositions and the functions of the crystal osmotic pressure and the colloid osmotic pressure in the intracellular colloid osmotic pressure can be analyzed by combining the method and the osmometer.

The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein essentially is free of hydroxyproline. This absence of hydroxyproline prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. Specific advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.

The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus.

The preparation method of polymerized hemoglobin with uniform molecular weight involved in the present invention comprises: (1) adsorbing hemoglobin on a stationary phase by a solid-phase adsorption method, and adding a homobifunctional reagent to carry out a polymerization reaction to obtain a polymerized product; (2) The polymer product generated in step (1) is eluted and collected with a high-salt buffer solution without amino groups, and then the collected product is separated and purified by chromatography to obtain polymerized hemoglobin; the hemoglobin used is human hemoglobin, bovine Hemoglobin and porcine hemoglobin; the polymerized hemoglobin prepared by the method is a polymerized hemoglobin (molecular weight is about 135 kilodaltons) of two molecules with uniform molecular weight, which overcomes the inhomogeneous defect of the polymerized product in the traditional glutaraldehyde preparation method; the Polymerized hemoglobin is easily separated from unpolymerized monomeric hemoglobin, and the colloid osmotic pressure is reduced due to the reduction of the number of protein colloids without significant change in viscosity.

The invention relates to an optimized anti-oxidative accelular protective solution, which has a critical effect on protection of structural completeness and biological nature of acellular tissues in the whole course of the decellularizing process. The protective solution is prepared from DMEM cellular culture medium L-histidine hydrochloride, allopurinol, chondroitin sulfate, low molecular dextran, hydroxypropyl methyl cellulose, HEPES buffer solution, dexamethason hydrochloride, reduced glutathione and levofloxacin. The protective solution is a light-red liquid with specific pH value, specific crystal and colloid osmotic pressure. The optimized anti-oxidative accelular protective solution is easily available in raw materials and economical in price, has strong applicability, wide application range and excellent anti-oxidation performance, and has a protective effect in the process of decellularizing biological tissues.

The invention provides a protection solution for preparing decellularized corneas. The protection solution is a PBS or HBSS buffer solution, wherein 5-12 g / L of hyaluronic acid, 5-20 g / L of chondroitin sulfate, and 3-10 g / L of low molecular weight dextran are added in the PBS or HBSS buffer solution. According to the protection solution, protective ingredients are added in the basic buffer solution, the prepared protection solution can maintain the colloid osmotic pressure of a preparing solution of decellularized corneas through selection of components and a proportion, and compared with a traditional preparing solution for decellularized corneas, cornea transparency decreasing caused by excessive swelling and missing of extracellular matrix ingredients such as collagen in the decellularization treatment process in a later stage can be remarkably relieved; besides, antibiotic ingredients such as tobramycin are added, breeding of bacteria such as pseudomonas aeruginosa, klebsiella biofilm, enterobacter and proteus which are likely to infect corneas is suppressed, and the contamination probability in the treatment process is avoided.

A pharmaceutical composition for treating brain edema and a preparation method therefor. The active ingredients of the compound pharmaceutical composition include sennoside A, cantharidin or a derivative thereof, nimodipine or nifedipine, cinepazide maleate and edaravone. Cellular experiments are used to find active drugs and combinations thereof that can reduce colloidal osmotic pressure and crystal osmotic pressure in brain cells to treat brain edema and provide new pharmaceutical use in clinical applications.